|
| 利塞膦酸钠联合雷洛昔芬治疗绝经后骨质疏松症疗效分析 |
| Efficacy of risedronate combined with raloxifene in the treatment of postmenopausal osteoporosis |
| |
| DOI：10.3969/j.issn.1006-7108.2019.08.022 |
| 中文关键词: 利塞膦酸钠 雷洛昔芬 绝经后骨质疏松症 骨密度 |
| 英文关键词:risedronate raloxifene postmenopausal osteoporosis bone mineral density |
| 基金项目: |
|
| 摘要点击次数: 1372 |
| 全文下载次数: 421 |
| 中文摘要: |
| 目的 观察利塞膦酸钠联合雷洛昔芬治疗绝经后女性骨质疏松症的效果。方法 将148例绝经后女性骨质疏松症患者随机分为治疗组和对照组，治疗组给予利塞膦酸钠联合雷洛昔芬治疗，对照组给予利塞膦酸钠治疗。在治疗前及治疗后12个月分别检测两组受试者腰椎及髋部骨密度、血清骨代谢指标、激素水平及研究期间药物不良反应和VAS评分的变化。结果 药物治疗后12个月，两组腰椎(L1~4)及左侧股骨颈的骨密度明显增加，治疗组的骨密度显著高于对照组(P＜0.05)；血清雌激素和孕酮水平均明显下降，皮质醇水平明显上升，与治疗前相比差异有统计学意义(P<0.05)，而对照组与治疗前相比差异无统计学意义(P>0.05)；治疗后两组血清P1NP及β-CTX较治疗前明显下降、BAP和BGP较治疗前明显上升，比较差异有统计学意义(P<0.05)，治疗组较对照组的改善更为明显(P<0.05)；治疗后两组患者VAS评分较治疗前显著降低，比较差异有统计学意义(P＜0.05)，治疗组较对照组降低得更为明显(P<0.05)；两组患者在研究期间的药物不良反应无统计学意义(P>0.05)。结论 利塞膦酸钠联合雷洛昔芬治疗骨质疏松症较单独使用利塞膦酸钠治疗的效果更为显著，且不增加药物副作用。 |
| 英文摘要: |
| Objective To observe the therapeutic effect of risedronate combined with raloxifene on postmenopausal osteoporosis. Methods 148 cases of postmenopausal osteoporosis were randomly divided into treatment group and control group. The treatment group was treated with risedronate combined with raloxifene and the control group was treated with risedronate alone. BMD of the lumbar spine and hip, serum bone metabolic index, hormone level, adverse drug reactions and VAS scores were measured before and after 12 months of treatment. Results 12 months after drug treatment, the BMD of lumbar vertebrae (L1-4) and left femoral neck increased significantly, and that of the treatment group was significantly higher than the control group (P<0.05). Compared with before treatment, serum estrogen and progesterone levels significantly decreased, and cortisol levels significantly increased in the treatment group (P<0.05), while there was no significant change in the control group (P>0.05).The levels of serum P1NP and β-CTX in the two groups were significantly lower than those before treatment, BAP and BGP levels were significantly higher than those before treatment (P<0.05), and the treatment group was more effective than the control group (P<0.05). The VAS score of the two groups was significantly lower than that of before treatment (P<0.05), and the treatment group was significantly lower than the control group (P<0.05). There were no statistically significant differences in adverse drug reaction between the two groups (P>0.05). Conclusion The treatment with risedronate and raloxifene is more effective than the use of risedronate alone, without increasing the side effects of the drug. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |